Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influenza A (H5N1) virus vaccine
- Development stage
- Approved
- Lead developer
- CSL Seqirus
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Influenza A (H5N1) virus vaccine is an inactivated monovalent vaccine indicated for active immunization to prevent disease caused by the H5N1 subtype of the influenza A virus. It is primarily used for individuals at increased risk of exposure to H5N1 avian influenza. The most widely available formulation in the United States is adjuvanted with either AS03 or MF59 to enhance immune response and enable dose sparing. The antigen component consists of inactivated split-virion H5N1 propagated in embryonated hen’s eggs and then chemically inactivated. The mechanism of action involves stimulating an immune response against hemagglutinin (HA), the primary surface glycoprotein on the H5N1 virus responsible for viral entry into host cells. This leads to production of neutralizing antibodies that protect against infection[2][3][6]. AUDENZ is one approved brand name manufactured by Seqirus[5]. Other manufacturers have produced similar vaccines globally.
- Brand names
- audenz
- Other names
- influenza a (h5n1) monovalent vaccineadjuvantedavian influenza h5n1 vaccinebird flu vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Influenza A (H5N1) virus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza A (H5N1) virus vaccine.